Stay updated with breaking news from Gary Meininger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SEATTLE, Dec. 01, 2023 -- Sana Biotechnology, Inc. , a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an abstract...
Dr. Douglas E. Williams as Head of Research and Development Dr. Gary Meininger as Chief Medical Officer SEATTLE, April 10, 2023 - Sana Biotechnology, Inc. , a... | April 10, 2023
Gathered for an emergency meeting, the Johnson & Johnson drug safety team painted an alarming scene: people taking the company's new blockbuster diabetes drug were falling gravely ill.
RARITAN, New Jersey--Gathered for an emergency meeting, the Johnson & Johnson drug safety team painted an alarming scene: People taking the company's
email article Teplizumab got a reticent thumbs-up from FDA advisors for an indication in delaying progression of at-risk patients to clinical type 1 diabetes (T1D). The agency's Endocrinologic and Metabolic Drugs Advisory Committee on Thursday voted 10-7 that sufficient evidence of benefit outweighed the risks for this novel biologic. However, a number on both sides indicated how narrowly they had come to making the opposite decision. "I voted 'yes' but had my finger over the 'no' button for a long time," said Jack Yanovski, MD, PhD, chief of the Section on Growth and Obesity at the Nat...